Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Price Target at $33.68

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has received an average recommendation of “Hold” from the thirty brokerages that are presently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a sell recommendation, fifteen have issued a hold recommendation and nine have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $33.76.

A number of equities analysts have recently commented on the stock. Robert W. Baird reduced their price objective on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. Wedbush initiated coverage on shares of Sarepta Therapeutics in a research report on Tuesday, December 9th. They issued an “outperform” rating and a $32.00 price target for the company. Guggenheim decreased their price objective on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Bank of America upped their price objective on Sarepta Therapeutics from $16.00 to $18.00 and gave the company an “underperform” rating in a research note on Wednesday, October 22nd. Finally, Barclays dropped their target price on Sarepta Therapeutics from $22.00 to $20.00 and set an “equal weight” rating for the company in a report on Wednesday, November 5th.

Insider Activity at Sarepta Therapeutics

In related news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the sale, the chief operating officer owned 193,300 shares in the company, valued at $4,312,523. This trade represents a 6.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of large investors have recently bought and sold shares of SRPT. Vanguard Group Inc. boosted its stake in Sarepta Therapeutics by 18.1% in the third quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after purchasing an additional 1,657,267 shares in the last quarter. Erste Asset Management GmbH raised its holdings in shares of Sarepta Therapeutics by 65.7% in the third quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock valued at $50,588,000 after buying an additional 1,064,530 shares during the last quarter. Aberdeen Group plc lifted its position in Sarepta Therapeutics by 13.6% during the 4th quarter. Aberdeen Group plc now owns 2,251,593 shares of the biotechnology company’s stock worth $48,454,000 after buying an additional 268,829 shares in the last quarter. First Trust Advisors LP grew its holdings in Sarepta Therapeutics by 209.1% during the 3rd quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock worth $37,380,000 after acquiring an additional 1,312,220 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Sarepta Therapeutics by 3.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,875,997 shares of the biotechnology company’s stock worth $32,085,000 after acquiring an additional 55,076 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Performance

SRPT stock traded down $0.18 during trading on Friday, reaching $21.13. 2,265,069 shares of the stock were exchanged, compared to its average volume of 2,697,644. Sarepta Therapeutics has a twelve month low of $10.41 and a twelve month high of $120.05. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $2.21 billion, a P/E ratio of -7.02, a price-to-earnings-growth ratio of 0.46 and a beta of 0.48. The stock has a 50 day simple moving average of $20.78 and a 200-day simple moving average of $19.69.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). The firm had revenue of $399.36 million for the quarter, compared to the consensus estimate of $331.51 million. Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The business’s revenue for the quarter was down 14.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.62 earnings per share. As a group, sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.